Alzheimer's disease (AD) is a growing healthcare problem. Early diagnosis and effective treatment would benefit patients and caregivers, as well as having economic implications. We conducted a survey of 741 caregivers of patients with AD in Australia, France, Italy, Spain and the UK to assess the current situation regarding the diagnosis and treatment of AD in routine clinical practice. The average time from when symptoms were first noticed by the caregiver to making the first doctor's appointment was 4 months, but 22% of caregivers waited more than 1 year before consulting a doctor. Although the majority of patients (74%) consulted their general practitioner first, the diagnosis was more likely to be made by a specialist; on average, there was a 1-year delay from when symptoms were first noticed by the caregiver to diagnosis. Access to AD care is restricted by many national healthcare systems. The delay in diagnosis imposed by such restrictions impacts on access to early and effective treatment.
Introduction
Alzheimer's disease (AD) is a significant healthcare burden, and as the elderly population, in particular the 'oldest old', increases, 1 AD will become an even greater healthcare challenge. Current estimates of the number of patients with dementia in the European Union range from 3.25 to 4.7 million, 2,3 of which AD is thought to account for 50 -70% of cases. 4, 5 In the majority of cases, patients with AD are cared for in the home by unpaid and untrained family members. 6 In addition to the progressive deterioration in memory, cognition and functional ability seen in such patients, the disease also impacts on the caregiver and other relatives of the patient. The burden of caring is significantly increased by the need to take over, or supervise, the patient's activities of daily living. In the early stages of AD, patients may no longer be able to prepare meals or use the telephone, and in the later stages may even be unable to wash, dress or toilet themselves. 6 Behavioural disturbances, such as wandering, agitation and aggression, are also common and are often difficult to manage. 6 This 'caregiver burden' is an important factor for physicians to consider when treating patients with AD.
The cholinesterase inhibitors (ChEIs) are currently one of the few treatments approved for AD. They improve cholinergic function in the brain by increasing levels of the neurotransmitter acetylcholine. 7 Clinical studies have shown that ChEI therapy, both in the earlier stages and in more advanced AD, provides symptomatic benefits 8 -20 and eases caregiver burden. 18, 21, 22 Similar benefits on symptoms were seen in an observational study reflecting everyday clinical practice. 23 Although AD is a progressive disease, ChEI therapy has also been associated with a slowing of the decline in global function compared with untreated patients. 12 The management of AD is associated with significant direct and indirect financial costs. 24 As the disease progresses the cost of care increases, with residential care accounting for the greatest proportion of the direct costs of AD. 25 Long-term treatment with the ChEI donepezil has been associated with economic benefits 26 and delayed nursing home placement. 27 Rapid diagnosis and early, effective treatment should therefore be important aims for the optimal management of AD in order to benefit patients and their caregivers, and potentially to reduce healthcare costs. Whether these aims are being met in everyday clinical practice is not known.
The objective of this multinational survey was to establish the current situation regarding access to diagnosis, treatment and care for patients with AD in clinical practice from the perspective of their caregivers and families.
Subjects and methods

SUBJECTS
Caregivers of patients with AD were recruited in Australia, France, Italy, Spain and the UK with the assistance of physicians, selfhelp charities, carer websites, pharmacists, day-care facilities and local or national Alzheimer's associations. All participants cared for patients who had been diagnosed with AD by a medical doctor. All caregivers were required to be related to and solely responsible for the patient, but were not paid as a caregiver. In addition, caregivers were excluded if they had taken part in any other market research on AD in the previous 3 months.
INTERVIEWS
Telephone interviews with caregivers, lasting approximately 30 min, were conducted in March and April 2002 by the following agencies: Taylor Nelson Sofres (Australia and UK), ICARE (France), ADACTA (Italy) and INNER Pharma (Spain). Questions covered the caregiver's perceptions of the diagnosis and treatment of AD in the patient, in particular the timescales involved, the use of medication and 'caregiver burden'. Taylor Nelson Sofres conducted the data coding, processing and analysis.
Results
CAREGIVER AND PATIENT INFORMATION
A total of 741 caregivers were interviewed. The distribution by country and characteristics of the patients with AD and their caregivers are shown in Table 1 . The majority of caregivers interviewed were female (77%), and the average length of time respondents had been caring for the relative with AD was 5 years. The average age of the patients was 77 years (≤ 75 years, 37%; 76 -80 years, 25%; > 80 years, 37%). Information regarding the care situation is also given in Table 1 . Over half (54%) of all caregivers interviewed spent every day (7 days/week) caring for the patient; the highest proportions were in Spain and the UK.
TIME TO FIRST DOCTOR'S APPOINTMENT
In 76% of cases, the patient's symptoms were first noticed by the caregiver being interviewed, and in 4% of cases they were noticed by the general practitioner (GP)/family doctor.
The symptoms most commonly reported to have first prompted caregivers to make the initial doctor's appointment for the patient were forgetfulness/memory problems (88%), difficulty performing everyday tasks (49%), a change or decline in the patient's behaviour (51%), a change in personality (39%) and depression (37%).
The average length of time from when AD symptoms were first noticed by the caregiver to when the patient first visited the doctor about these symptoms was 4 months ( Fig. 1 ). Only 17% of patients saw a doctor immediately. Among the respondents who did not make an appointment with a doctor immediately, the average time from when symptoms were first noticed to the first appointment was 6 months. Twenty-two per cent of the caregivers waited more than 1 year before making the initial appointment. 
DIAGNOSIS OF AD
In 74% of cases, patients first presented to their GP/family doctor. This proportion was lower in Italy and Spain, where patients have greater direct access to specialists ( Table 2 ).
In 70% of cases, the doctor with whom the patient first discussed their symptoms was not the doctor who eventually diagnosed AD. Patients initially presenting to a specialist were four times more likely to be diagnosed by the same doctor compared with patients first presenting to their GP/family doctor.
A neurologist was mentioned by 52% of respondents as the doctor who eventually diagnosed AD (Table 3 ). This was more likely in France, Spain and Italy, whereas in Australia the diagnosis was most likely to be made by a geriatrician or the GP/family doctor, and in the UK by a psychiatrist or the GP/family doctor ( Table 3 ).
The average time taken from when symptoms were first noticed to the diagnosis of AD was 12 months (Fig. 2 ). For 20% of patients there was a delay of over 2 years between caregivers noticing the symptoms and the diagnosis of AD. Overall, 31% of caregivers were dissatisfied with the time taken from first seeking help to diagnosis. As expected, respondents receiving a diagnosis 
MEDICATION RECOMMENDED AT DIAGNOSIS
The majority of respondents (73%) stated that medication was recommended to the patient around the time of diagnosis. Specialists were more likely to recommend medication for AD than GPs: 77% of patients diagnosed by a specialist were recommended medication compared with 45% diagnosed by a GP (Fig. 3) . When AD was diagnosed, medication was recommended to a higher proportion of patients in France, Italy and Spain (82%, 85% and 85%, respectively) than in Australia and the UK (53% and 46%, respectively). According to the respondents in this survey, the main reasons given by doctors for not recommending medication at the time of diagnosis were that there was 'no cure currently available' (18%) and that the disease was 'too advanced to warrant treatment' (15%).
Of patients recommended medication at the time of diagnosis, 79% were recommended a ChEI. Patients with AD diagnosed by a specialist were more likely to be prescribed a ChEI than those diagnosed by a GP/family doctor. Younger patients (< 80 years old) were much more likely to be recommended a ChEI at the time of diagnosis than older patients.
MEDICATION BEING TAKEN AT THE TIME OF THE SURVEY
Overall, almost one-third (30%) of the patients were not receiving any AD medication at the time of the survey. The percentage was highest in Australia and the UK (44% and 47%, respectively). At the time of the survey, 57% of the patients were taking a ChEI, with a higher frequency in France, Italy and Spain (77%, 73% and 56%, respectively) than in Australia and the UK (41% and 21%, respectively). The majority (70%) of caregivers were satisfied with the medication the patient was receiving. The data indicated that the caregivers of those receiving a ChEI were less likely to have given up their jobs to care for the patient (9%) than those currently receiving another type of medication (25%) or those receiving no medication at all (27%).
TREATMENT ISSUES
Whether patients with AD were treated by their GP or by a specialist is listed in Table 4 . Overall, 82% of caregivers were satisfied with the doctor currently treating the patient, and 76% were satisfied with the overall treatment the patient had received.
When respondents were asked how confident they were concerning the skill of their GP/family doctor in diagnosing and treating AD, around half responded positively (Fig. 4) , and around three-quarters agreed that GPs understand the impact AD has on both the patient and caregiver. In 79% of cases, it was agreed that GPs are easily accessible.
Overall, respondents perceived the specialists positively, but 41% of the caregivers did not agree that specialists are easily accessible; this response was more likely in Australia and the UK.
CAREGIVER BURDEN
When asked to describe some of their feelings associated with caring for someone with AD, many caregivers used negative words such as tiring (77%), demanding (66%), depressing (57%) and frustrating (51%). Half the caregivers said that they sometimes suffer depression. Only 34% and 26% of respondents, respectively, used the words rewarding and/or fulfilling. Overall, 75% of respondents felt there was a burden placed on them as a caregiver, and 25% considered it to be a 'severe burden' (Fig. 5 ). Not being able to have a social life (75%) and/or holidays (63%) were reported by most caregivers as the sacrifices they made in order to care for the patient, along with not spending as much time with children/other dependents, the general financial burden, and giving up or reducing work.
The majority of caregivers (77%) felt that the healthcare system in their country placed insufficient emphasis on AD and provided insufficient assistance in caring for the patient (61%). Just over half felt that AD care would be eased if it was easier to obtain effective medication for the patient. The overwhelming majority of caregivers were in agreement that, for patients with AD, small improvements mean a lot on a day-to-day basis.
In addition to information received from their doctor, half of all the caregivers interviewed used Alzheimer's associations to Other popular sources of information included magazine or newspaper articles (32%) and educational leaflets/booklets provided by their doctor (25%). Respondents also used Alzheimer's associations for emotional support (58%) and counselling (39%), in addition to disease education and information on new treatments and respite care.
DISCUSSION
The findings of this survey highlight a number of stages in the diagnosis and treatment of AD in which changes could be made to benefit physicians, patients and their caregivers. There is a wealth of clinical trial data indicating that the treatment of mild to moderate AD in the short and long term with ChEIs has beneficial effects on the symptoms of AD, on caregiver burden, and also has economic benefits. It is therefore important that patients receive a diagnosis and appropriate treatment as early as possible and remain on therapy for as long as possible. In this survey, nearly one-quarter of all caregivers waited more than 1 year Educating the general public about the early signs and symptoms of AD, the availability of symptomatic treatments, and consequently the importance of seeking early medical advice should be undertaken at every possible opportunity. Removing the perceived stigma associated with dementia should also be a priority and may encourage patients and caregivers to see a healthcare professional earlier.
Evidence from this survey suggests that, while most patients present first to a GP, the eventual diagnosis is more likely to be made by a specialist. On average, a period of 1 year elapsed from when AD symptoms were first noticed by caregivers to an eventual diagnosis of AD. As expected, differences were seen between countries, reflecting the differing healthcare systems in the countries surveyed. Access to AD care is restricted by many national healthcare systems. In the UK, for example, only specialists are permitted to diagnose AD and initiate treatment. 28 This often involves a referral from the patient's GP/family doctor, inevitably increasing the time from the first appointment to eventual diagnosis, and further delaying early and effective treatment. Ideally, national healthcare systems should empower GPs/family doctors and allied healthcare professionals to diagnose and treat AD. The development of simple screening tests for AD that can be conducted quickly and easily, may be a useful aid for the GP/family doctor. Alternatively, access to specialists much earlier in the diagnostic pathway may reduce the time to diagnosis and treatment; however, this may depend on the structure of each national healthcare system and, unless specialists are already freely available, this will add costs or continue the delays.
Almost one-third of caregivers interviewed in this survey indicated that the patient was not receiving any medication for their condition. The main reasons given by doctors for not recommending treatment included 'there is no cure for AD' and that the patient's condition was 'too advanced'. While there is currently no available 'cure' for AD, ChEIs have proven symptomatic benefits in many patients, even in the more advanced stages of the disease, and may slow the decline in function. These effects have positive impacts on both patients and caregivers. Although these benefits may be regarded as modest in some cases, even modest improvements can mean a lot on a day-to-day basis, as confirmed by the majority of caregivers in this survey.
Prescription of AD medications, including ChEIs, varied from country to country in this survey, as expected when comparing different healthcare systems. The cost of medication is likely to be an issue cited by healthcare authorities, but treatment of AD with ChEIs has been associated with economic benefits compared with no treatment, and has also been associated with a delay to nursing home placement, which is likely to reduce the direct costs of AD care.
Although changes in guidelines, with their inherent restrictions, may take time to implement within national healthcare systems, in view of the increasing elderly population, steps must be taken to effectively manage the ever-increasing number of patients with AD worldwide. Dementia is a common, diagnosable condition, and the early stages can, and should, be managed in primary care. What is needed is the political will, together with the encouragement of healthcare purchasers, to do so.
